178 related articles for article (PubMed ID: 22836596)
1. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Serebruany VL; Atar D
Thromb Haemost; 2012 Sep; 108(3):412-4. PubMed ID: 22836596
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Editorial on Serebruany, Atar: 'Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?' (Thromb Haemost 2012; 108.3).
Verheugt FW
Thromb Haemost; 2012 Sep; 108(3):410-1. PubMed ID: 22836950
[No Abstract] [Full Text] [Related]
3. Delays of event adjudication in the TRITON trial.
Serebruany VL
Cardiology; 2010; 115(3):217-20. PubMed ID: 20234133
[TBL] [Abstract][Full Text] [Related]
4. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Mahaffey KW; Held C; Wojdyla DM; James SK; Katus HA; Husted S; Steg PG; Cannon CP; Becker RC; Storey RF; Khurmi NS; Nicolau JC; Yu CM; Ardissino D; Budaj A; Morais J; Montgomery D; Himmelmann A; Harrington RA; Wallentin L;
J Am Coll Cardiol; 2014 Apr; 63(15):1493-9. PubMed ID: 24561148
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
7. The TRITON versus PLATO trials: differences beyond platelet inhibition.
Serebruany VL
Thromb Haemost; 2010 Feb; 103(2):259-61. PubMed ID: 20024505
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
Wiviott SD; Desai N; Murphy SA; Musumeci G; Ragosta M; Antman EM; Braunwald E
Am J Cardiol; 2011 Oct; 108(7):905-11. PubMed ID: 21816379
[TBL] [Abstract][Full Text] [Related]
9. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Serebruany VL
Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
11. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
12. Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies.
Serebruany VL
Cardiology; 2014; 127(3):190-5. PubMed ID: 24457905
[TBL] [Abstract][Full Text] [Related]
13. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
15. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
Wiviott SD; Braunwald E; Angiolillo DJ; Meisel S; Dalby AJ; Verheugt FW; Goodman SG; Corbalan R; Purdy DA; Murphy SA; McCabe CH; Antman EM;
Circulation; 2008 Oct; 118(16):1626-36. PubMed ID: 18757948
[TBL] [Abstract][Full Text] [Related]
16. Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
Mahaffey KW; Hafley G; Dickerson S; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Lopes RD
Am Heart J; 2013 Aug; 166(2):240-249.e1. PubMed ID: 23895806
[TBL] [Abstract][Full Text] [Related]
17. Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
De Servi S; Navarese EP; D'Urbano M; Savonitto S
Curr Med Res Opin; 2011 Nov; 27(11):2117-22. PubMed ID: 21919581
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor FDA approval issues revisited.
Serebruany VL
Cardiology; 2012; 122(3):144-7. PubMed ID: 22832506
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
